genedrive plc
Research genedrive plc (GDR) on Bullrun: market cap GBX 1.93B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGDR
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyGBX
- Market capGBX 1.93B
- Financial periodFY2025
- RevenueGBP 764.00K
- Revenue growth130.1%
- Net income-GBP 5.23M
- Free cash flow-GBP 5.17M
Valuation Snapshot
latest market cap is GBX 1.93B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 764.00K | -GBP 5.23M | -GBP 5.17M | n/a | -0.01 | GBP 1.18M | GBP 0 | GBP 1.44M |
| FY2024 | GBP 332.00K | -GBP 7.08M | -GBP 3.80M | n/a | -0.04 | GBP 5.19M | GBP 19.00K | GBP 5.36M |
| FY2023 | GBP 55.00K | -GBP 5.15M | -GBP 3.86M | n/a | -0.04 | GBP 2.60M | GBP 241.00K | GBP 2.04M |
| FY2022 | GBP 49.00K | -GBP 4.68M | -GBP 4.66M | n/a | -0.04 | GBP 4.59M | GBP 16.00K | GBP 5.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | GBX 1.93B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is genedrive plc's market cap?
genedrive plc's market capitalization is GBX 1.93B.
What does genedrive plc do?
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel.